To this point, two phase I/II trials are enrolling patients to evaluate the combination of metformin (an inhibitor of OXPHOS) with vemurafenib (NCT01638676) or dabrafenib and trametinib (NCT02143050) in patients with metastatic melanoma with activating mutations in the BRAF gene. Here, BRAF is linked to metastatic melanoma.